VHeFT I (hydralazine ISDN), 1986 trial summary

A randomised clinical trial investigating the effect of hydralazine-ISDN versus placebo in patienst with chronic congestive heart failure and cardiac dilatation (CT ratio>0.55) or LVEF <45% in association with reduced exercise tolerance

Studied treatment	hydralazine 300mg/d ISDN 160mg/d
Control treatment	placebo

Patients	patienst with chronic congestive heart failure and cardiac dilatation (CT ratio>0.55) or LVEF <45% in association with reduced exercise tolerance
Group sizes	186 / 273

Blindness	double blind	Inclusion period	march 1980-june 1985
Follow-up duration	2.3 y (range 0.5-5.7 years)	Centers
Lost to FU	ND	geographical localisation
Primary endpoint		Design	Parallel groups
ArretTrt1	ND
PeriodeInclusion	march 1980-june 1985

Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-52 [PMID: 3520315] link to pdf add to Mendeley

Registering number	(see trial on clinicaltrials.gov)
Code Name

VHeFT I (hydralazine ISDN), 1986 trial summary PDF trial summary